Acomorbid 76-year-old man was treated locally in August 2021 with transcatheter edge-to-edge repair (TEER) using an XTW MitraClip (Abbott Vascular) to the A2/P2 scallops. Hecontinued to experience New York Heart Association functional class IIIb symptoms with severe residual regurgitation and mitral stenosis caused by the clip and significant mitral annular calcification (Figure 1).

Transesophageal echocardiography demonstrated a 3-dimensional vena contracta area of 0.88 cm2 and a mitral valve area of 1.8 cm2 (Figures 2A and 2B). By cardiac-gated computed tomography angiography, the valve measured 45 mm
39 mm, and his pre- dicted neo–left ventricular outflow tract was >300 mm2.

Under the agreement, BIS will initiate the US commercialization activities for ŌNŌCOR’s ŌNŌ Retrieval Device. Through the collaboration, ŌNŌCOR positions itself for success as an innovator of safety technology in the growing market of catheter-based interventions, while BIS expands its portfolio around its strong congenital and structural heart focus.

Cardiologists at the UW Medicine Heart Institute recently performed a first-in-the-world procedure, detaching and retrieving a clip device from a patient’s mitral valve and placing a replacement biologic valve — all through a catheter. Previously this sequence of tasks had been performed only via open surgery.

The team at Children's Hospital Los Angeles (CHLA, @ChildrensLA), led by Dr. Darren Berman, Director of Congenital Interventional Catheterization with CHLA's Heart Institute, percutaneously removed a large fibrotic thrombus from a 14-year-old patient using a combination of ŌNŌ, endovascular snares, and electrocautery.

ŌNŌCOR LLC is excited to announce the first-in-human use of the ŌNŌ endovascular retrieval system for removal of an intracardiac tumor. Intracardiac tumors affect thousands of patients around the world annually, but prior to ŌNŌ, open-heart surgery was required for removal.

ŌNŌCOR Receives FDA Clearance for Novel Endovascular Retrieval Technology.

The ŌNŌ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions.